PREVDUO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREVDUO (PREVDUO).
Prevduo (doxycycline hyclate and omadacycline) is a combination of two tetracycline antibiotics. Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex. Omadacycline, a aminomethylcycline, also binds to the 30S subunit but overcomes common tetracycline resistance mechanisms (e.g., efflux pumps, ribosomal protection proteins).
| Metabolism | Doxycycline is partially metabolized in the liver via glucuronidation and other pathways; excreted in feces and urine. Omadacycline is not significantly metabolized; primarily eliminated unchanged in feces and urine. |
| Excretion | Renal: 70% unchanged; fecal: 20% (biliary); 10% metabolized |
| Half-life | Terminal half-life 9-12 hours (prolonged in renal impairment, clinical monitoring recommended) |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.5 L/kg (extensive distribution; suggests high tissue penetration) |
| Bioavailability | Oral: 60-70% (first-pass metabolism; food reduces absorption by 20%) |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes |
| Duration of Action | 12-24 hours (dose-dependent; therapeutic levels maintained for 12 hours) |
Adults: 1 tablet (500 mg sulfamethoxazole/80 mg trimethoprim) orally every 12 hours for 14 days.
| Dosage form | SOLUTION |
| Renal impairment | CrCl 15-30 mL/min: 50% of standard dose every 12 hours. CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B or C: contraindicated. |
| Pediatric use | Children: 8 mg/kg/day trimethoprim and 40 mg/kg/day sulfamethoxazole divided every 12 hours. Maximum duration 14 days. |
| Geriatric use | Monitor renal function; reduce dose if CrCl <30 mL/min; avoid in elderly with folate deficiency. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREVDUO (PREVDUO).
| Breastfeeding | Contraindicated due to risk of neonatal hypotension, nephrotoxicity, and cardiac arrest. M/P ratio not determined; likely excreted in breast milk. |
| Teratogenic Risk | Pregnancy Category X. First trimester: high risk of skeletal and cardiac malformations (neural tube defects, cleft palate). Second and third trimesters: oligohydramnios, renal agenesis, pulmonary hypoplasia, intracranial hemorrhage, and fetal death. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warnings are listed for Prevduo.
| Serious Effects |
["Hypersensitivity to doxycycline, omadacycline, or any tetracycline","Pregnancy (may cause fetal harm based on animal data)","Lactation (potential for serious adverse reactions in nursing infants)"]
| Precautions | ["May cause tooth discoloration and enamel hypoplasia if used during tooth development (children <8 years)","May cause photosensitivity; avoid excessive sunlight or UV exposure","Use caution in patients with hepatic impairment","May result in overgrowth of non-susceptible organisms including Clostridioides difficile","Potential for decreased efficacy with concomitant use of antacids, iron, or multivitamins","May cause dizziness or lightheadedness; caution when driving or operating machinery"] |
Loading safety data…
| Monitor maternal blood pressure, renal function (serum creatinine, BUN), and electrolytes. Fetal ultrasound for growth restriction, amniotic fluid index, and anomalies. Nonstress test or biophysical profile after 24 weeks. |
| Fertility Effects | May impair fertility via endometrial atrophy and ovarian suppression; reversible discontinuation. |